Seres stockholders approve sale of VOWST business to Nestlé; close expected Sept 30

Seres Therapeutics, Inc.

Stockholders voted 77.1M for, 7.1M against, and 0.2M abstain to approve the sale of VOWST business to Société des Produits Nestlé S.A.
Non-binding advisory compensation proposal for named executives also passed (63.1M for, 20.9M against, 0.4M abstain).
Transaction expected to close on September 30, 2024, subject to customary closing conditions.
VOWST is a microbiome therapeutic; the sale was originally announced under an asset purchase agreement dated August 5, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.